Authors
Rieneke T Lugtenberg, Stefanie de Groot, Ad A Kaptein, Maarten J Fischer, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Danielle Cohen, Hiltje de Graaf, Joan B Heijns, Johanneke EA Portielje, Agnes J van de Wouw, Alex LT Imholz, Lonneke W Kessels, Suzan Vrijaldenhoven, Arnold Baars, Marta Fiocco, Jacobus JM van der Hoeven, Hans Gelderblom, Valter D Longo, Hanno Pijl, Judith R Kroep
Publication date
2020/11/11
Journal
Breast Cancer Research and Treatment
Pages
1-18
Publisher
Springer US
Description
Purpose
In the phase II DIRECT study a fasting mimicking diet (FMD) improved the clinical response to neoadjuvant chemotherapy as compared to a regular diet. Quality of Life (QoL) and illness perceptions regarding the possible side effects of chemotherapy and the FMD were secondary outcomes of the trial.
Methods
131 patients with HER2-negative stage II/III breast cancer were recruited, of whom 129 were randomly assigned (1:1) to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and the day of neoadjuvant chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) questionnaires EORTC-QLQ-C30 and EORTC-QLQ-BR23; the Brief Illness Perception Questionnaire (BIPQ) and the Distress Thermometer were used to assess these outcomes at baseline, halfway chemotherapy …
Total citations
Scholar articles
RT Lugtenberg, S de Groot, AA Kaptein, MJ Fischer… - Breast cancer research and treatment, 2021